Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
ISSN: 2471-9552
Manal Mohamed Saber and Matthias Clauss
Minia University, Egypt
Indiana University School of Medicine, Indianapolis, Indiana
Scientific Tracks Abstracts: Immunotherapy (Los Angel)
Objectives: Establishing diagnostic and prognostic factors are very important in the management of Non-Hodgkin Lymphoma (NHL). Our aim was to evaluate the clinical significance of serum cytokines and immunological markers, in NHL patients for assessing treatment response and prognosis of patients. Methods: Serum EMAP-II, IL-19, IL-10, IL-24, TGF-�?², CD3, CD5, CD10, CD19, CD20, CD22, CD23, CD68, CD79a, CD99, LCA, bcl-2, bcl-6 and anticardiolipin (aCA) IgM, aCA IgG, antinulclear antibodies (ANA) levels were measured in the serum of 64 NHL patients before and after treatment with CHOP-based chemotherapy by enzyme-linked immunosorbent assay. Correlations of marker levels to the laboratory, and clinicopathological markers were performed. Results: Serum levels of EMAP-II, IL-10, CD3, CD5, CD10, CD19, CD20, CD99 and aCA IgG were higher before therapy and decreased significantly thereafter (P<0.001). Serum CD68, CD79a and bcl-6 did not change after therapy. Significantly higher levels of IL-19, IL-24, bcl-2, CD22, CD23, LCA, TGF- �?², ANA, and aCA IgM were demonstrated in patients with relapse (P<0.001). Significant associations were found between serum markers, clinicopathological and laboratory findings. Conclusion: Cytokines and immunological markers can serve as useful diagnostic markers in NHL patients. They assessed response to therapy. Serum IL-19, IL-24, bcl-2, CD22, CD23, LCA, TGF- �?², ANA, and aCA IgM proved to be the most sensitive predictor of advanced disease and poor prognosis.
Dr Manal Mohamed Saber, has earned her PhD from Nottingham, UK. she is focusing on cancer studies, EMAP II, immune suppression, molecular, cellular and laboratory techniques at a high level. She received excellent training in molecular and cellular techniques at the highest international level and has previously worked with cancer and immunology studies. Her dedication to cure cancer got her involved in cancer studies
Email: manal.saber@mu.edu.eg